On July 5, 2020, Brian Stuglik was appointed to the Board of Directors of Puma Biotechnology, Inc. Mr. Stuglik will serve on the Board for a term expiring at the 2021 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. In connection with his appointment to the Board, Mr. Stuglik was also appointed to the Commercial Committee of the Board (the “Commercial Committee”). Mr. Stuglik has served as the Chief Executive Officer of Verastem, Inc., since July 2019 and as a member of its Board of Directors since September 2017. On July 6, 2020, Frank E. Zavrl notified the Company of his decision to resign from the Board, effective immediately.
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.
PUMA BIOTECHNOLOGY, INC. 
